The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I adult brain tumor consortium (ABTC) trial of ABT-888 (veliparib), temozolomide (TMZ), and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM) including pharmacokinetic (PK) data.
Lawrence Kleinberg
Research Funding - Abbott Laboratories
Jeffrey G. Supko
Research Funding - Abbott Laboratories
Tom Mikkelsen
Research Funding - Abbott Laboratories
Jaishri O'Neill Blakeley
Research Funding - Abbott Laboratories
Glen Stevens
Research Funding - Abbott Laboratories
Xiaobu Ye
Research Funding - Abbott Laboratories
Serena Desideri
Research Funding - Abbott Laboratories
Samuel Ryu
Research Funding - Abbott Laboratories
Bhardwaj Desai
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
Vincent L. Giranda
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
Stuart A. Grossman
Research Funding - Abbott Laboratories